Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| CELGENE CORP /DE/CELG · Entity 15781 | SEE REMARKS | July 30, 2018 | August 01, 2018 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & CFO | February 24, 2014 | February 26, 2014 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | Director | May 22, 2019 | May 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,446 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,446 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,441 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
CELGENE CORP /DE/
Report date July 30, 2018 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 20,285 |
Reported balance
After 2018-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-30 · Grant · Acquired 20,285 · Balance 20,285 F2: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019.
F2: The option was issued pursuant to the Company's 2017 Stock Incentive Plan.
Merck & Co., Inc.
Report date February 24, 2014 · Filed February 26, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,553.902 |
Reported balance
After 2014-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-02-24 · Grant · Acquired 18,662 · Balance 149,553.902 F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards.
F2: Holdings include shares acquired in dividend reinvestment transactions.
YIELD10 BIOSCIENCE, INC.
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2029-05-22 | Direct | 10,000 |
Reported balance
After 2019-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 10,000 · Balance 10,000 F1: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof.
F2: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/22/19, beginning on 8/22/2019 and ending on 5/22/2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2013 Filed Nov 14, 2013 16:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-023472 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,631.902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 37,325 | $44.98 | $1,678,878.50 |
DisclosureSEC source: 0001225208-13-011732 · doc4.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,325 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 19,354 | $44.98 | $870,542.92 |
DisclosureSEC source: 0001225208-13-011732 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,631.902 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 37,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011732 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,985.902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 206,119 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011732 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,119 Underlying: Common Stock · 206,119 shares Expires 2023-05-05 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 17,178 | $42.52 | $730,408.56 |
DisclosureSEC source: 0001225208-13-005765 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,660.902 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 234,004 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011187 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,004 Underlying: Common Stock · 234,004 shares Expires 2022-05-01 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 16,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011187 · doc4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,289 Underlying: Common Stock · 16,289 shares Expires 2015-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| April 24, 2012 Filed Apr 26, 2012 19:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 17,550 | $38.27 | $671,638.50 |
DisclosureSEC source: 0001225208-12-010296 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,550 shares Expires 2012-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| April 24, 2012 Filed Apr 26, 2012 19:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 8,135 | $38.27 | $311,326.45 |
DisclosureSEC source: 0001225208-12-010296 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,482.902 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 24, 2012 Filed Apr 26, 2012 19:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 17,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-010296 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,617.902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2012 Filed Mar 1, 2012 20:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 13,069 | $38.38 | $501,588.22 |
DisclosureSEC source: 0001225208-12-006222 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,067.902 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/27/09. Performance shares were paid out at 117 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 12, 2011 Filed Aug 15, 2011 18:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 200 | $31.80 | $6,359.80 |
DisclosureSEC source: 0001225208-11-019891 · doc4.xml · nonDerivative · entry 5 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,998.9013 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 12, 2011 Filed Aug 15, 2011 18:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 1,635 | $31.77 | $51,943.95 |
DisclosureSEC source: 0001225208-11-019891 · doc4.xml · nonDerivative · entry 4 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,798.9013 Read SEC document |
| August 12, 2011 Filed Aug 15, 2011 18:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 4,000 | $31.80 | $127,200.00 |
DisclosureSEC source: 0001225208-11-019891 · doc4.xml · nonDerivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,163.9013 Read SEC document |
| August 12, 2011 Filed Aug 15, 2011 18:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 4,155 | $31.78 | $132,045.90 |
DisclosureSEC source: 0001225208-11-019891 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,163.9013 Read SEC document |
| August 12, 2011 Filed Aug 15, 2011 18:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 5,810 | $31.81 | $184,816.10 |
DisclosureSEC source: 0001225208-11-019891 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,008.9013 Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 238,806 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-11-013365 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,806 Underlying: Common Stock · 238,806 shares Expires 2021-05-03 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 4, 2012. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 17,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-013365 · doc4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,505 Underlying: Common Stock · 17,505 shares Expires 2014-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 11,700 | $32.19 | $376,623.00 |
DisclosureSEC source: 0001225208-11-007808 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,700 shares Expires 2011-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 4,253 | $32.19 | $136,904.07 |
DisclosureSEC source: 0001225208-11-007808 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,198.9013 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 28, 2011 Filed Mar 1, 2011 20:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007808 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,451.9013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2011 Filed Feb 24, 2011 17:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 9,083 | $32.34 | $293,744.22 |
DisclosureSEC source: 0001225208-11-007029 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,751.9013 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/29/08. Performance shares were paid out at 122 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 13, 2010 Filed Nov 16, 2010 17:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 40,000 | $34.71 | $1,388,400.00 |
DisclosureSEC source: 0001225208-10-024932 · doc4.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2013-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: 40,000 Restricted Stock Units vested on November 13, 2010 (reduced by 18,540 withheld for taxes) and 40,000 will vest on November 13, 2013 Read SEC document |
| November 13, 2010 Filed Nov 16, 2010 17:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 18,540 | $34.71 | $643,523.40 |
DisclosureSEC source: 0001225208-10-024932 · doc4.xml · nonDerivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,460 Read SEC document |
| November 13, 2010 Filed Nov 16, 2010 17:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-024932 · doc4.xml · nonDerivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:31 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 210,084 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012613 · doc4.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,084 Underlying: Common Stock · 210,084 shares Expires 2020-05-06 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:31 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 37,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012613 · doc4.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exe V-P & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,325 Underlying: Common Stock · 37,325 shares Expires 2013-05-07 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 93,600 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 6 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,600 shares Expires 2019-04-23 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 62,400 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 5 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,400 shares Expires 2018-02-28 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $57.49 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 4 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2017-11-12 F3 · price: This option vests in five equal annual installments beginning November 13, 2008, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F3 · derivative.exercise_date: This option vests in five equal annual installments beginning November 13, 2008, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 17,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 3 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,550 shares Expires 2012-04-24 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 2 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,700 shares Expires 2011-02-28 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051308 · c92130_4x0.xml · derivative · entry 1 KELLOGG PETER N · CIK 0001226287 · Exec. V.P. & C.F.O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2013-11-13 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. 40,000 restricted stock units will vest on November 13, 2010 and 40,000 restricted stock units will vest on November 13, 2013. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. 40,000 restricted stock units will vest on November 13, 2010 and 40,000 restricted stock units will vest on November 13, 2013. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. 40,000 restricted stock units will vest on November 13, 2010 and 40,000 restricted stock units will vest on November 13, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.